Guillain-Barré syndrome.
Autor(es): Randall David P.
Resumo: In the fascinating world of neurologic diseases, Guillain-Barré syndrome (GBS) has set itself apart as one of the most intriguing. We are far from a definitive understanding of the etiology, pathology, and mechanisms of GBS, but we do have both some insight and some ways to manage and treat those afflicted.1 GBS has such a dramatic presentation that it has been recognized for more than a century. Almost 150 years ago, Landry described a rapidly ascending progressive paralysis that was not due to polio. Guillain and Barré described the syndrome through a series of articles.2,3 In the last 50 years the understanding of this and other autoimmune diseases has markedly expanded. The defining criteria of GBS have been widened to include a variety of syndromes that are all part of the spectrum GBS. In the simplest terms Guillain-Barré is an acute, acquired, autoimmune disorder of the peripheral nervous system that tends to be both monophasic and have a good recovery.4 GBS is thought to be triggered by infections and other immunogenic stimuli, although the exact cause is not fully understood. GBS remains a feared disease that strikes people of all ages across the world.
Imprenta: Disease-a-Month, v. 56, n. 5, p. 256-261, 2010
Identificador do objeto digital: 10.1016/j.disamonth.2010.02.004
Descritores: Guillain-Barre Syndrome - Epidemiology
Data de publicação: 2010
